In our final ASCO 2025 episode, Michael is joined by Prof Jeanne Tie, colorecal cancer lead at Peter MacCallum Cancer Centre to discuss some of the many highlights in colorectal and anal cancer. Starting with the practice changing BREAKWATER study, combining chemotherapy with encorafenib and cetuximab, they also discuss the plenary study ATOMIC III, the CHALLENGE study examining structured exercise programs for patients with resected cancer, as well as the emerging role of ctDNA in colon and anal SCC. Studies discussed in this episode BREAKWATER CHALLENGE ATOMIC III INTERAACT 2 DYNAMIC III For more episodes, resources and blog posts, visit www.inquisitiveonc.com Please find us on Twitter @InquisitiveOnc! If you want us to look at a specific trial or subject, email us at
[email protected] Art courtesy of Taryn Silver Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/ Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.
